PNT — POINT Biopharma Global Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.33bn
- $998.03m
- $226.58m
Point Biopharma Global Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: POINT Biopharma Makes Strategic Investment In Commercial-Scale Alpha-Emitting Isotope Manufacturer
Brief: Point Biopharma Reports First Quarter 2023 Financial Results And Provides Business Highlights
Point Biopharma Global Inc Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Brief: Lantheus And Point Biopharma Announce FDA Grants Fast Track Designation For Lu-Pnt2002
Brief: Point Biopharma Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: POINT Biopharma Posts Q4 Net Loss USD 14.2 Mln
Point Biopharma Global Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview
Brief: Point Biopharma Confirms No Disruptions To The Manufacturing And Clinical Supply For The 177Lu-Pnt2002 Splash Trial, A Phase 3 Study In Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc)
Point Biopharma up on enrollment completion for cancer therapy trial
Brief: Point Biopharma Global Completes Randomization In PNT2002’S Phase 3 Splash Trial
U.S. STOCKS ON THE MOVE-Viridian, Carvana, Titan Machinery
U.S. STOCKS ON THE MOVE-3M Co, copper miners, Build-A-Bear Workshop
U.S. STOCKS ON THE MOVE-Crypto stocks, gold miners, Horizon Therapeutics
Point Biopharma's Prostate Cancer Therapy Expected To Succeed In Trial: SVB
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Point Biopharma Global Inc Reports Results For The Quarter Ended In September: Earnings Summary
Point Biopharma slumps on deal with Lantheus for lead cancer therapies
Brief: Point Biopharma Global Inc Reports Quarterly Net Loss Per Share Of $0.26